作者: Alan Sandler , Robert Gray , Michael C. Perry , Julie Brahmer , Joan H. Schiller
DOI: 10.1056/NEJMOA061884
关键词: Pemetrexed 、 Internal medicine 、 Cediranib 、 Hazard ratio 、 Carboplatin 、 Medicine 、 Gastroenterology 、 Respiratory disease 、 Surgery 、 Lung cancer 、 Motesanib 、 Bevacizumab
摘要: Background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. Methods Between July 2001 …